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Abstract This review covers recent data on interactions of
nicotinic acetylcholine receptors (AChR) with snake venom pro-
teins (K- and U-neurotoxins, ‘weak’ toxins recently shown to act
on AChRs), as well as with peptide K-conotoxins from Conus
snails. Mutations of AChRs and toxins, X-ray/nuclear magnetic
resonance structures of K-neurotoxin bound to AChR frag-
ments, and the X-ray structure of the acetylcholine-binding pro-
tein were used by several groups to build models for the K-
neurotoxin^AChR complexes. Application of snake toxins and
K-conotoxins for pharmacological distinction of muscle, neuro-
nal and neuronal-like AChR subtypes and for other medical
purposes is brie£y discussed.
( 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Nicotinic acetylcholine receptors (AChR) are an abundant
family of transmitter-gated ion channels classi¢ed into two
major groups: muscle-type and neuronal (see reviews
[1^3])1. The receptor from the Torpedo electric ray belongs
to the ¢rst group and is composed of ¢ve subunits (two K,
and one L, Q, and N) arranged pseudo-symmetrically along a
central axis. Mammalian muscle AChRs have a similar struc-
ture, with an O subunit instead of Q in the mature form. Sev-
eral versions of K (K2^K10) and non-K subunits (L2^L4) were
found in neuronal AChRs which are heteromeric (combina-
tions of K and L subunits) or homooligomeric (for example,
built of ¢ve K7 subunits). Neuronal AChRs may be postsyn-
aptic or presynaptic, the latter regulating the release of diverse
neurotransmitters; neuronal-like AChR were also detected in
non-neuronal tissues [2].
Current ideas on the structural organization of all AChRs
[1] are largely based on experimental studies of the Torpedo
AChR. It was the use of snake venom K-neurotoxins from
cobras and kraits (see reviews [4^7]) that made possible iso-
lation of preparative amounts of this receptor and subsequent
comprehensive analysis. The aim of this review is to show how
K-neurotoxins and other snake toxins are used today in AChR
structural studies, for detection of pharmacologically distinct
AChR subtypes and for other medical purposes. K-Conotox-
ins from poisonous marine snails Conus, another sophisticated
tool in AChR research, will also be considered.
2. Sequences, three-dimensional structure and speci¢city of
snake toxins and K-conotoxins acting on diverse AChRs
Short-chain K-neurotoxins from snake venoms (Table 1)
contain 60^62 amino acid residues and four disul¢de bridges,
and the long-chain toxins 66^74 residues and ¢ve disul¢des
[4]. The spatial structure of both has a three-¢ngered fold:
four disul¢des make a hydrophobic core from which originate
three loops forming a L-structure (Fig. 1). Some snake toxins
not targeting AChRs have homologous cysteines and a similar
spatial structure [6,7].
Short- and long-chain K-neurotoxins e⁄ciently block both
Torpedo and muscle AChRs, but only the long ones act on
neuronal homooligomeric K7 AChRs. Heteromeric neuronal
AChRs are not sensitive to K-neurotoxins, some of them are
blocked by U-bungarotoxins. The ¢fth disul¢de in loop II of
U-bungarotoxins and of long K-neurotoxins is essential for
their recognition of the respective neuronal AChRs [7].
Snake venoms contain proteins of low toxicity, named
‘weak, miscellaneous, non-conventional toxins, or long neuro-
toxin homologs’ [6^8]) having the ¢fth disul¢de in the N-ter-
minal loop I (Fig. 1). They have recently been shown to block
muscle-type, K7 and K7-like AChRs [8^14]. Nuclear magnetic
resonance (NMR) and X-ray analyses [12,15,16] revealed in
weak toxins a three-¢nger fold. In spite of low toxicity, some
weak toxins bind distinct AChRs irreversibly [11,12,14].
A loop I disul¢de makes weak toxins structurally more
similar than other three-¢nger toxins to the Ly6 proteins of
the mammalian immune system and to a related protein lynx1
(‘prototoxin’) of the nervous system [17]. Membrane-anchored
lynx1 is in proximity to neuronal K7 and K4L2 AChRs, mod-
ulating their properties. The disul¢de in loop I is essential for
lynx1 activity [17].
Waglerins (Table 1), neurotoxic peptides from the pit viper
T. wagleri, block muscle AChRs. Whereas most K-neurotoxins
bind with similar a⁄nity to the two binding sites in the
muscle-type AChRs (situated at the interfaces between K-sub-
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Table 1
Representatives of snake and snail toxins acting on diverse AChRs
Toxin Number of aa
residues
S^S bonds Target acetylcholine receptor
Snake venoms
Short-chain K-neurotoxins (erabutoxins L. fasciata, K-toxins
N. nigricollis and N. mossambica, neurotoxin II N. oxiana)
60^62 4 Torpedo (K2LQN) and muscle (K2LQN or
K2LON)
Long-chain K-neurotoxins (K-bungarotoxin B. multicinctus,
K-cobratoxin N. kaouthia)
66^74 5 Torpedo, mammalian muscle; neuronal K7;
K7-like Cl3-channels on Aplysia and
L. stagnalis neurons
Long-chain U-neurotoxins (U-bungarotoxins B. multicinctus) 66 5 Neuronal K3L2 (K4L2)
‘Weak’ toxins (WTX N. kaouthia, candoxin B. candidus) 63^66 5 Torpedo and muscle, neuronal K7; K7-like
Cl3-channels of L. stagnalis
Waglerins (from T. wagleri) 20^24 1 Torpedo and muscle
Marine snail Conus venoms
K-Conotoxins G1, M1, SI, EI 13^18 2 Torpedo and muscle
K-Conotoxins (ImI and ImII C. imperialis, PnIB C. pennaceus,
[A10L] PnIA)
12, 16 2 K7; K7-like Cl3 channels on Aplysia
neurons
PnIA C. pennaceus, GIC C. geographus 16 2 K3L2
K-Conotoxin MII C. magus 16 2 K3L2, K6
K-Conotoxin AuIB C. aulicus 15 2 K3L4
KA-Conotoxins (PIVA C. purpurascens, EIVA C. ermineus) 25^30 3 Torpedo and muscle
i-Conotoxins (i-PIIIE and i-PIIIF C. purpurascens) 24 3 Torpedo (non-competitive block)
Fig. 1. Top: Ribbon presentation of the spatial structures of neurotoxin II Naja oxiana ([29], PDB code 1NOR), K-bungarotoxin Bungarus mul-
ticinctus ([30], PDB 1KFH); non-conventional toxin bucandin Bungarus candidus ([16], PDB 1IJC), K-conotoxin G1 Conus geographus ([31],
PDB 1NOT), and K-conotoxin ImI Conus imperialis ([32], PDB 1IMI). L-Strands and helical regions are shown. The L-strand termini are
marked by numbers. Additional disul¢de bridges, characteristic for long-chain K-neurotoxins and non-conventional toxins, are colored in violet,
and the corresponding cysteines are numbered. Roman numerals (I, II, and III) mark three loops of toxins. Bottom: Ribbon representation of
the model of Torpedo AChR^K-bungarotoxin complex ([33], PDB 1LK1). Left to right: top and front views.
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units and their ‘non-K’ counterparts), waglerins distinguish
them, having much higher a⁄nity for the K/O site [18].
One group of K-conotoxins (Table 1) inhibit muscle-type
AChRs, while others block distinct neuronal AChRs [19].
KA-conotoxins compete, like the respective K-conotoxins,
with K-neurotoxins for binding to Torpedo receptor, while
i-conotoxins are non-competitive blockers [19]. The spatial
structures of K-conotoxins acting on various neuronal AChRs
possess a similar fold di¡ering somewhat from that of ‘muscle’
K-conotoxins (Fig. 1). i-Conotoxins have an extended con-
formation like W-conotoxins blocking sodium channels [20].
K-Conotoxins allow researchers to distinguish diverse
AChRs (Table 1) and even discriminate the two binding sites
in the muscle-type AChRs, the di¡erence in the a⁄nities de-
pending on a particular K-conotoxin and the AChRs species.
K-Conotoxins di¡er in relative selectivity: K-conotoxin MII
has been considered speci¢c for K3L2 AChRs [19], but was
recently shown to block also the K6-containing AChRs [21].
Similar to MII in a⁄nity for K3L2 AChRs, K-conotoxin GIC
is much more selective, its a⁄nity for any other neuronal
subtype being 100-fold lower, and for muscle AChR 10 000-
fold lower [22]. K-Conotoxins may be isolated from venoms or
¢rst identi¢ed via analysis of cDNA and then obtained by
peptide synthesis [22,23]. The latter provides unlimited possi-
bilities for ‘chemical mutagenesis’, including insertion of non-
natural amino acids [24]. The case of K-conotoxin PnIA/
[A10L]PnIA (Table 1) illustrates a mutation-induced shift in
selectivity [25,26].
Distinct K-conotoxins can act on the same AChR di¡er-
ently: PnIB, ImI and ImII all block the K7 AChR, the binding
sites for the ¢rst two being non-identical but overlapping
[27,28] (Table 2), while there is no overlap for ImII which,
contrary to others, does not compete with K-bungarotoxin
[23].
3. Interacting surfaces of toxins and receptors
There are no solved structures for AChR complexes with
snake toxins or K-conotoxins. Below are discussed recent mu-
tational analyses of pair-wise interactions of toxins with the
whole-size receptors, as well as X-ray/NMR studies of K-neu-
rotoxin complexes with the receptor fragments or with com-
binatorial peptides (Table 2).
The earlier work (reviewed in [5^7]) revealed that short-
chain K-neurotoxins bind to muscle-type AChRs using loops
I, II and III. For long K-neurotoxins loop III is less impor-
tant, and additional contributions come from the toxin’s C-
terminus. Some residues in K-cobratoxin (W25, D27, R33,
Table 2
Identi¢ed interactions between toxin and receptor residues
Toxin Receptor or receptor fragment
K-Bungarotoxin Torpedo K1(182^202) [33] K7 (178^196) [30] HAP(187^199) [41]
T6 W187, Y189 HW187
A7 F186
T8 W187, K185, L199 Y189
S9 W187, Y189 F186
P10 W187
I11 W187, Y189 F186 Y189
D30 Y190 R188, Y190
R36 W149, Y190, Y198 F186, Y194 S192
K38 T191, Y190 E188 E191
V39 Y187, Y194
V40 Y187, E188
H68 Y189, T191, C192 S193
Q71 T191, C192, P194 L194
K-Cobratoxin Torpedo K1(181^198) [42] K7^5HT3 [34]a
I9 Y189, T196
T10 T191
F29 W54
I32 Y189
R33 Y189 W148, Y187, P193, Y194
K35 Y189 D163, F186
R36 Y190 Y187, D196
F65 F186, P193
R68 Y190
K69 Y190
N Toxin NmmI Muscle AChR [37]
K27 QE176, QW55, KV188
R33 KL119, KY190, QW55
R36 KV188, KY190
Waglerin Muscle AChR (K2LQO) [18] O G57, D59, Y115, D173b
K-Conotoxin M1 Muscle AChR(K2LN2) [35]
A7, P6, Y12, KY198
Y12 N S36, N Y113, N I178
K-Conotoxin ImI K7^5HT3 [27]a
R7 Y195
K-Conotoxin PnIB K7-5HT3 [28]c
L10 W149
K-Conotoxin MII K3L2 AChR [36] K3 K185, K3 I188, L2 T59b
aChimera made of the K7 chick AChR (extracellular domain) and the rest of 5HT3 (serotonin) receptor.
bThe receptor residues determining the high a⁄nity are shown; their counterparts in the toxin have not been identi¢ed.
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F29, R36, F65) are essential for binding both to muscle and to
neuronal K7 AChRs, whereas K23 and K49 are required only
for the former, and C26^C30 and K35^ for the latter [7].
Earlier results of a⁄nity labeling [5,6] and recent mutational
analyses [7] show that binding of di¡erent neurotoxins takes
place at the interfaces of two K-subunits with N and Q (or O) in
muscle-type receptors, and at the K/L and K/K interfaces in
heteromeric and homooligomeric neuronal AChRs, respec-
tively. Weak toxins apparently bind at subunit interfaces,
one toxin (candoxin) distinguishing the two sites in muscle
AChR [8]. The binding sites for K-neurotoxins, other antago-
nists and agonists are made by several fragments of K-sub-
units (A, B, C loops) and residues in the adjacent subunits (D,
E and F loops) [3,34], loop C (fragment 180^200) being im-
portant for practically all kinds of ligands [18] (Table 2).
Synthetic K-conotoxin analogs made it possible to locate
positions essential for binding, while AChR mutations identi-
¢ed the residues governing the a⁄nity of the K/Q (K/O) and K/N
sites [19]. Hydrophobic residues of K-conotoxin M1 are im-
portant for binding to muscle AChRs [35]. According to pair-
wise mutations, recognition of K7 AChR by PnIB is governed
by hydrophobic interaction of toxin L10 with the receptor’s
W149 [28], whereas for ImI it is the R7^Y195 pair [27].
Among K-conotoxins acting on heteromeric neuronal AChRs,
interactions of K-conotoxin MII with K3L2 AChRs were
studied in most detail [36] (Table 2). Variability of functional
groups grafted on the same sca¡old (Fig. 1) allows diverse
neuronal-type K-conotoxins to target distinct AChR subtypes.
The same principle and a three-¢nger fold are employed by
snake toxins against di¡erent AChRs or other targets (mus-
carinic receptors, acetylcholinesterase etc.) [6].
Table 2 shows that R33 from the central loop of K-cobra-
toxin and K-toxin NmmI interacts with several residues in the
muscle and K7 AChRs. It was noted earlier that R33/F29 in
K-cobratoxin have a topology similar to R7/W10 in K-cono-
toxin ImI which might be important for K7 AChR recognition
[6]. Interestingly, the similarity in disposition of a pair of
positively charged/aromatic residues in the scorpion and sea
anemone toxins, di¡ering in sequences and spatial structure,
underlie their common mode of blocking the potassium chan-
nels [38].
The X-ray structure of the mollusk acetylcholine binding
protein (AChBP) [39] provided the basis for visualizing the
AChR^toxin interactions. Having at best 24% homology
with extracellular N-terminal domains of AChR subunits,
this protein contains virtually all residues essential for
AChR binding of agonists and antagonists. Indeed, AChBP
binds such compounds, including K-neurotoxins, and K-bun-
garotoxins resin was employed for isolating AChBP [40]. By
molecular modeling the K7 AChR extracellular domain using
the AChBP structure, a model of the K-cobratoxin complex
with K7 AChR has been proposed that embraces abundant
crosslinking and mutagenesis data [34].
The AChBP structure was also used for models of K-neuro-
toxin^AChR complexes based on the X-ray or NMR struc-
tures of K-neurotoxins with synthetic peptides [30,33,41,42].
Fragments from the region 180^200 of muscle-type K-subunits
have long been known to bind these toxins, although much
less e⁄ciently than the complete receptors. Binding of K-bun-
garotoxin was also detected with the respective fragments of
the K7 subunit [43]. Interestingly, an insertion of the K7 frag-
ment into the K3 subunit made the K3L2 AChR sensitive to K-
bungarotoxin [44]. Combinatorial peptide HAP (high a⁄nity
peptide showing some similarity to the region 187^199) bound
K-bungarotoxin with nanomolar a⁄nity, and the X-ray anal-
ysis of the complex revealed that the peptide conformation
imitated the L-hairpin region 182^193 of the AChBP [41].
This ¢nding as well as direct observations of intermolecular
interactions (including H-bonds between the peptide and neu-
rotoxin) (Table 2) were used for docking K-bungarotoxin to
the AChBP [41]. A similar approach was employed for build-
ing the model of K-bungarotoxin complex with the Torpedo
AChR starting from the H-NMR structure of the toxin com-
plex with the K182^202 fragment [33]. In all analogous models
[30,33,34,42], a portion of a toxin molecule penetrates between
the subunits roughly at the half-height of the extracellular
domain. (The idea of toxin penetration was earlier put for-
ward based on photoa⁄nity labeling [5].)
Experiments stimulated by analyses of AChBP structure
unraveled new toxin^AChR interactions: G152 and P193
form an H-bond in AChBP, and their simultaneous mutation
in K7 AChR decreased the a⁄nity for K-bungarotoxin 100-
fold [45].
The current models of the toxin^AChR complexes will
probably undergo some revision, since a recent publication
by Unwin and co-authors [46] shows that the N-terminal
extracellular domain of the Torpedo AChR includes a portion
of the transmembrane fragment MI. It means that not only
the distance of the bound toxin from the membrane surface
may di¡er, but additional interactions with AChR appear
possible which might a¡ect the disposition of bound toxins.
4. Present and possible future applications of snake and snail
toxins
Distinct AChRs are involved in many vitally important
processes and their malfunctioning may be the cause or con-
sequence of various diseases. Therefore, the determination of
the density of AChR subtypes is of practical importance, and
the appropriately labeled K-neurotoxins and K-conotoxins are
used for this purpose, along with antibodies and other com-
pounds. The cholinergic system is involved in cognitive func-
tions, and the available data show a decrease in di¡erent
neuronal AChRs as a result of Alzheimer’s disease [2]. Re-
cently, the involvement of K7 AChR in angiogenesis [47] and
in the regulation of immune reactions via production of tumor
necrosis factor [48] was demonstrated. In both cases either the
respective knock-out mutants or blocking the receptors with
K-bungarotoxin were used. The K7 AChRs are overexpressed
in small cell lung carcinoma of smokers. In vitro experiments
demonstrated that the malignant growth can be stopped by
blocking these receptors with K-neurotoxins or K-conotoxins
[49]. In this respect, weak toxins which have low toxicity but
irreversibly block these receptors are of possible pharmaco-
logical use. There are already precedents when polypeptide or
peptide toxins as such are used for medical purposes: for
example, the Ca2þ channel blocker g-conotoxin MVIIA
(trade name Ziconotide) is on the market as treatment of
chronic pain [50]. The literature data indicate both the in-
volvement of distinct neuronal AChRs in analgesia [2] and
analgesic activity of some K-conotoxins [51]. Therefore, there
are reasons to expect drugs to be designed on the basis of
naturally occurring or modi¢ed peptides or polypeptides tar-
geting diverse AChRs.
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